Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Study of the Combination of Ibrutinib Plus Venetoclax in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Next Previous
Trial Profile

Phase 2 Study of the Combination of Ibrutinib Plus Venetoclax in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibrutinib (Primary) ; Venetoclax (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms CAPTIVATE
  • Sponsors Pharmacyclics

Most Recent Events

  • 12 Jun 2025 Results presented in the Janssen Cilag Media Release.
  • 19 Nov 2024 According to a Johnson & Johnson media release, results from this study will be presented at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego from December 7-10.
  • 14 Jun 2024 According to Johnson & Johnson media release , the company announced publication of updated findings of this study which were featured in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #7009) in Chicago from 31 May - 4 June and as an encore presentation at the European Hematology Association (EHA) Congress (Poster #P675) in Madrid, Spain, from 13-16 June 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top